Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 28, 2026
TENAX THERAPEUTICS, INC. (TENX)
A forensic read on TENAX THERAPEUTICS, INC. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
3.6
Altman Z-score
Clean
Earnings quality
1
Forensic signals
-56.3%
ROE
$356M
Market cap
TENAX THERAPEUTICS, INC. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is 3.6, placing it in the Safe zone. 1 forensic signal was flagged in its latest SEC filings, led by share-count dilution.
What the filings flag
+4.0%/yrShare-count dilution.Diluted share count changed +40% over the last 10 years to FY2025 (+4.0%/yr). The count is GROWING — existing holders are being diluted. That's ~4.0% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2015 has been diluted ~40%.
Key fundamentals
Free Cash Flow$-35.8M
Return on Equity-54.2%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on TENAX THERAPEUTICS, INC.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about TENX's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown